BiotechTube
Pure Biologics

Pure Biologics

Wroclaw, Poland· Est.
purebiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.8M

Overview

Pure Biologics is a publicly traded biotech company based in Poland, specializing in the development of novel antibody and aptamer-based therapeutics for immuno-oncology. It has built a proprietary technology platform for selecting active molecules and has progressed two lead candidates, PB004 and PB003G, into Phase 0 clinical studies with FDA approvals. The company's strategy is to achieve financial independence by commercializing its therapeutic candidates to fund further advanced R&D projects.

OncologyImmuno-oncology

Technology Platform

Proprietary platform for the selection and development of biologically active molecules, including antibodies and aptamers, for therapeutic applications.

Funding History

2
Total raised:$9.8M
Series A$8M
Seed$1.8M

Opportunities

Positive Phase 0 data for lead candidate PBA-0405 de-risks further development and enhances partnership potential.
The growing immuno-oncology market and the novelty of its aptamer platform provide avenues for creating valuable, differentiated assets.

Risk Factors

High clinical development risk as early-phase success does not guarantee later-stage outcomes.
Financial risk as a pre-revenue public company requiring continued capital raises, potentially causing dilution.
Intense competition in immuno-oncology from larger, well-funded global biopharma firms.

Competitive Landscape

Operates in the highly competitive global immuno-oncology sector, competing with major pharma and biotech companies developing antibody and cell therapies. Its differentiation lies in its proprietary aptamer platform and its position as a pioneer in novel biologic development within Central Europe.

More companies in Immunotherapy / Immuno-Oncology →More companies in Poland →